All Outputs (2)

Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial (2024)
Journal Article
Devereux, G., Cotton, S., Nath, M., McMeekin, N., Campbell, K., Chaudhuri, R., …Lipworth, B. J. (2024). Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial. Journal of the American Medical Association, https://doi.org/10.1001/jama.2024.8771

Importance: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Observational studies report that β-blocker use may be associated with reduced risk of COPD exacerbations. However, a recent trial repor... Read More about Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial.

Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites (2024)
Journal Article
Crooks, M. G., Cummings, H., Morice, A. H., Sykes, D., Brooks, S., Jackson, A., & Xu, Y. (2024). Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites. NPJ Primary Care Respiratory Medicine, 34(1), Article 6. https://doi.org/10.1038/s41533-024-00363-0

Short-acting beta-agonist (SABA) over-use in asthma is harmful for patients and the environment. The Investment and Impact Fund (IIF) 2022/2023 financially rewarded English primary care networks that achieved specific targets, including reducing SABA... Read More about Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites.